Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

355
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
355
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

125
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
125
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

749
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
749
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

399
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
399

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteasomal inhibition compromises microvascular integrity via distinct effects on non-immune endothelial cells and immune cells.

Frontiers in immunology·2026
Same author

Animal Models of Malaria-Associated Acute Kidney Injury.

Seminars in nephrology·2025
Same author

Cancer Drug Bortezomib, a Proteasomal Inhibitor, Triggers Cytotoxicity in Microvascular Endothelial Cells via Multi-Organelle Stress.

bioRxiv : the preprint server for biology·2025
Same author

Metabolomic and chemometric analyses of St. John's wort and related Asian Hypericum species linked to bioactivity.

Journal of ethnopharmacology·2024
Same author

Pathology of Severe Malaria.

Pathogens (Basel, Switzerland)·2023
Same author

Novel Experimental Mouse Model to Study Malaria-Associated Acute Kidney Injury.

Pathogens (Basel, Switzerland)·2023

Related Experiment Video

Updated: Jul 2, 2025

In Vivo Tracking of Edema Development and Microvascular Pathology in a Model of Experimental Cerebral Malaria Using Magnetic Resonance Imaging
09:04

In Vivo Tracking of Edema Development and Microvascular Pathology in a Model of Experimental Cerebral Malaria Using Magnetic Resonance Imaging

Published on: June 8, 2017

6.5K

Exploring adjunctive therapies for cerebral malaria.

Johanna Bensalel1,2, Julio Gallego-Delgado1,2,3

  • 1Ph.D. Program in Biology, The Graduate Center, The City University of New York, New York, NY, United States.

Frontiers in Cellular and Infection Microbiology
|February 27, 2024
PubMed
Summary

Cerebral malaria (CM) remains a deadly complication of malaria, especially in children. New adjunctive therapies are urgently needed as current treatments fail to address CM's underlying pathology.

Keywords:
adjunctive therapycerebral malariachild mortalityendotheliumsevere malaria

More Related Videos

Selection of Plasmodium falciparum Parasites for Cytoadhesion to Human Brain Endothelial Cells
10:09

Selection of Plasmodium falciparum Parasites for Cytoadhesion to Human Brain Endothelial Cells

Published on: January 3, 2012

19.1K
Isolation and Analysis of Brain-sequestered Leukocytes from Plasmodium berghei ANKA-infected Mice
12:48

Isolation and Analysis of Brain-sequestered Leukocytes from Plasmodium berghei ANKA-infected Mice

Published on: January 2, 2013

12.8K

Related Experiment Videos

Last Updated: Jul 2, 2025

In Vivo Tracking of Edema Development and Microvascular Pathology in a Model of Experimental Cerebral Malaria Using Magnetic Resonance Imaging
09:04

In Vivo Tracking of Edema Development and Microvascular Pathology in a Model of Experimental Cerebral Malaria Using Magnetic Resonance Imaging

Published on: June 8, 2017

6.5K
Selection of Plasmodium falciparum Parasites for Cytoadhesion to Human Brain Endothelial Cells
10:09

Selection of Plasmodium falciparum Parasites for Cytoadhesion to Human Brain Endothelial Cells

Published on: January 3, 2012

19.1K
Isolation and Analysis of Brain-sequestered Leukocytes from Plasmodium berghei ANKA-infected Mice
12:48

Isolation and Analysis of Brain-sequestered Leukocytes from Plasmodium berghei ANKA-infected Mice

Published on: January 2, 2013

12.8K

Area of Science:

  • * Neurology
  • * Infectious Diseases
  • * Pharmacology

Background:

  • * Cerebral malaria (CM) is a severe neurological complication of malaria, predominantly affecting pediatric populations.
  • * Standard artemisinin-based combination therapies (ACT) reduce malaria parasite levels but do not effectively combat CM's pathological mechanisms.
  • * High mortality rates persist due to ACT's inability to address blood-brain barrier disruption, endothelial dysfunction, and hyperinflammation.

Purpose of the Study:

  • * To review potential therapeutic targets and treatments for cerebral malaria.
  • * To summarize findings on previously tested therapies, including those found ineffective or harmful.
  • * To highlight the critical need for adjunctive therapies in managing CM.

Main Methods:

  • * Literature review and summary of existing research on cerebral malaria therapeutics.
  • * Analysis of pathogenic mechanisms contributing to CM.
  • * Evaluation of the efficacy and safety of various treatment strategies.

Main Results:

  • * Current ACT treatments are insufficient for CM due to their failure to target key pathological pathways.
  • * Several potential therapeutic targets and agents for CM have been identified.
  • * Some previously investigated treatments have shown limited efficacy or adverse effects.

Conclusions:

  • * Adjunctive therapies are essential to improve outcomes for cerebral malaria patients.
  • * Further research into promising therapeutic agents is warranted.
  • * Targeting CM-specific pathologies is crucial for reducing mortality and morbidity.